Why Repigmentation in Vitiligo So Often Starts at the Hair Follicle

Anyone who has watched a vitiligo patch respond to phototherapy or topical treatment has probably noticed the pattern: pigment does not return as a smooth wave from the edges. Instead, tiny brown dots appear scattered across the white area, usually centered on hair follicles, and then slowly expand and merge. Dermatologists call this perifollicular repigmentation, and it is the most common way vitiligo skin recovers color. The reason comes down to where the body keeps its backup supply of pigment cells.

In healthy skin, melanocytes sit along the basal layer of the epidermis, producing melanin and handing it off to surrounding keratinocytes. In vitiligo, an autoimmune attack driven largely by CD8 positive T cells targeting melanocyte antigens destroys or disables these epidermal melanocytes. That is why lesional skin looks stark white under a Wood's lamp: there is essentially no functional pigment machinery left in the surface layer.

But the epidermis is not the only place melanocytes live. The hair follicle contains a second, better protected population. In the bulge region of the outer root sheath, a zone partway down the follicle, sit melanocyte stem cells. These cells are immature. They do not yet produce melanin, and critically, they express little or none of the melanocyte-specific proteins, such as tyrosinase and gp100, that the immune system uses to recognize and attack mature pigment cells. The follicle also enjoys a degree of relative immune privilege, with locally reduced antigen presentation. Together, low antigen expression and a sheltered location mean these stem cells often survive the autoimmune assault that wipes out their epidermal cousins.

When treatment quiets the immune attack, whether through topical corticosteroids, calcineurin inhibitors, JAK inhibitors, or narrowband UVB phototherapy, these dormant stem cells get their chance. UV light in particular does double duty. It suppresses local immune activity, and it stimulates keratinocytes to release signaling molecules including stem cell factor, endothelin 1, and alpha melanocyte stimulating hormone. In response, melanocyte stem cells activate, proliferate, differentiate into pigment-producing melanocytes, and migrate upward along the follicle into the epidermis. Once there, they spread outward horizontally. Each follicle becomes a small island of returning color, which is exactly the dotted pattern patients see.

This mechanism has real clinical consequences, and it explains several patterns that otherwise seem arbitrary.

Hairless and hair-poor sites respond worst. The lips, fingertips, knuckles, palms, soles, and bony prominences have few or no terminal hair follicles, which means little or no stem cell reservoir. These are consistently the most treatment-resistant sites in vitiligo, and no amount of phototherapy can recruit melanocytes that are not there. For these areas, surgical options such as melanocyte-keratinocyte cell suspension transplantation or punch grafting, which physically import melanocytes from unaffected donor skin, are often the only realistic route to repigmentation, and only once disease activity is stable.

White hair inside a patch is a warning sign. When the hairs within a vitiligo lesion have turned white, a finding called leukotrichia, it suggests the autoimmune process has reached into the follicle and damaged the reservoir itself. Patches with extensive leukotrichia repigment poorly with medical therapy for the same reason hairless skin does: the backup supply is gone. This is one of the practical prognostic markers clinicians assess before setting expectations.

Marginal repigmentation exists but is slower. Some pigment does creep in from the healthy border of a patch, as melanocytes at the edge proliferate and migrate inward. This marginal pattern is real but typically limited to a few millimeters, which is why large patches depend heavily on the follicular route. A combined pattern, dots inside plus a darkening rim, generally predicts the best outcome.

Early dots are a good sign, not a flaw. Patients sometimes worry that the speckled appearance during treatment looks worse than the uniform white patch. It is worth stating plainly: those dots are the visible evidence that the stem cell reservoir survived and treatment is working. With continued therapy over months, islands typically enlarge and coalesce. Repigmentation is slow biology. Stem cell activation, migration, and horizontal spread commonly take three to six months to become obvious and a year or more to approach completion, which is why guidelines emphasize sustained treatment courses rather than quick trials.

The follicular reservoir also frames where research is heading. Newer approaches aim not only to suppress the immune attack, the focus of JAK inhibitors, but also to actively stimulate stem cell activation and migration, for example through Wnt pathway signaling, which appears blunted in vitiligo lesions. The long-term vision is a two-part strategy: stop the fire, then deliberately restock the field.

For patients, the takeaway is practical. Ask where your patches are, whether the hairs within them still have color, and what pattern of repigmentation your clinician expects. Those three details, all rooted in follicle biology, do more to predict your outcome than the name of any single treatment.

Related reading: Why Vitiligo Repigmentation So Often Starts as Tiny Dots Around Hairs.